Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Karthik Dhatchinamoorthy, Jeff D. Colbert, Kenneth L. Rock
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 630

Showing 1-25 of 630 citing articles:

Toward personalized treatment approaches for non-small-cell lung cancer
Meina Wang, Roy S. Herbst, Chris Boshoff
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1345-1356
Closed Access | Times Cited: 642
A guide to antigen processing and presentation
Novalia Pishesha, Thibault J. Harmand, Hidde L. Ploegh
Nature reviews. Immunology (2022) Vol. 22, Iss. 12, pp. 751-764
Closed Access | Times Cited: 380
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Seong Keun Kim, Sun Wook Cho
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 224
Macrophages at the interface of the co-evolving cancer ecosystem
Daan J. Kloosterman, Leila Akkari
Cell (2023) Vol. 186, Iss. 8, pp. 1627-1651
Open Access | Times Cited: 161
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
Carlo Genova, Chiara Dellepiane, Paolo Carrega, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 148
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
Bastian Kruse, Anthony Buzzai, Naveen Shridhar, et al.
Nature (2023) Vol. 618, Iss. 7967, pp. 1033-1040
Open Access | Times Cited: 137
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Paul Shafer, Lauren Kelly, Valentina Hoyos
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 136
A pan-cancer single-cell panorama of human natural killer cells
Fei Tang, Jinhu Li, Lu Qi, et al.
Cell (2023) Vol. 186, Iss. 19, pp. 4235-4251.e20
Open Access | Times Cited: 131
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Nicholas A. Maskalenko, Dmitry Zhigarev, Kerry S. Campbell
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 8, pp. 559-577
Open Access | Times Cited: 127
Emerging phagocytosis checkpoints in cancer immunotherapy
Yue Liu, Yanjin Wang, Yanrong Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 126
Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Yanyan Xu, Jingyuan Xiong, Xiyang Sun, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 12, pp. 4327-4347
Open Access | Times Cited: 116
Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine
Mohammadreza Kasravi, Armin Ahmadi, Amirhesam Babajani, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 111
Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
Jingjing He, Xinxin Xiong, Han Yang, et al.
Cell Research (2022) Vol. 32, Iss. 6, pp. 530-542
Open Access | Times Cited: 104
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Paolo Tarantino, Chiara Corti, Peter Schmid, et al.
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 98
Natural killer cell therapies
Éric Vivier, Lucas Rebuffet, Émilie Narni-Mancinelli, et al.
Nature (2024) Vol. 626, Iss. 8000, pp. 727-736
Closed Access | Times Cited: 96
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
Raquel S. Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 84
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Muthulekha Swamydas, Elena V. Murphy, James J. Ignatz-Hoover, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 79
Colorectal cancer immunotherapy-Recent progress and future directions
Wen Zhao, Lujia Jin, Peng Chen, et al.
Cancer Letters (2022) Vol. 545, pp. 215816-215816
Closed Access | Times Cited: 71
A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population
Shinsuke Yoshida, Tomoaki Kato, Yoshiko Sato, et al.
Med (2022) Vol. 4, Iss. 1, pp. 51-66.e10
Open Access | Times Cited: 71
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
Susana García‐Recio, Toshinori Hinoue, Gregory Wheeler, et al.
Nature Cancer (2022)
Open Access | Times Cited: 68
Enzyme-Instructed Peptide Assembly Favored by Preorganization for Cancer Cell Membrane Engineering
Yinghao Ding, Debin Zheng, Li‐Min Xie, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 8, pp. 4366-4371
Closed Access | Times Cited: 67
Genetic immune escape landscape in primary and metastatic cancer
Francisco Martínez-Jiménez, Peter Priestley, Charles Shale, et al.
Nature Genetics (2023) Vol. 55, Iss. 5, pp. 820-831
Open Access | Times Cited: 67
A membrane-associated MHC-I inhibitory axis for cancer immune evasion
Xufeng Chen, Lu Qiao, Hua Zhou, et al.
Cell (2023) Vol. 186, Iss. 18, pp. 3903-3920.e21
Closed Access | Times Cited: 67
Challenges in developing personalized neoantigen cancer vaccines
Peter D. Katsikis, Ken J. Ishii, Christopher Schliehe
Nature reviews. Immunology (2023) Vol. 24, Iss. 3, pp. 213-227
Closed Access | Times Cited: 58
Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation
Wanzun Lin, Li Chen, Haojiong Zhang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 53
Page 1 - Next Page

Scroll to top